Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
public offering
Biotech
FDA extends review of Gamida Cell's approval by 3 months
The FDA has extended the review period for Gamida Cell's approval package of its stem cell transplant therapy by three months.
Max Bayer
Nov 22, 2022 10:55am
BMS-backed Immatics touts early data, prompting $110M offering
Oct 10, 2022 1:23pm
Day One spends day 2 hitting up public markets for $150M
Jun 15, 2022 11:16am
Zai Lab aims for $750M to bankroll licensing deals
Apr 20, 2021 3:30pm
Annexon, AlloVir gun for $100M IPOs
Jul 7, 2020 8:05am
Twist Bioscience nets $140M plus a slew of new DNA partnerships
Feb 26, 2020 12:03pm
